Stockreport

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Saliv...

Actuate Therapeutics, Inc. - Common stock  (ACTU) 
PDF Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3ß expression may help identify pa [Read more]